On July 22, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) issued Advisory Opinion 24-05, evaluating two manufacturer-sponsored assistance programs under the federal Anti-Kickback...more
8/1/2024
/ Anti-Kickback Statute ,
Department of Health and Human Services (HHS) ,
Fertility Treatments ,
Financial Aid ,
Life Sciences ,
Manufacturers ,
OIG ,
Patient Assistance Programs ,
Patients ,
Pharmaceutical Industry ,
Travel Expenses
On June 17, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted a favorable Advisory Opinion 24-03 (“AO 24-03”) involving a pharmaceutical manufacturer’s proposed patient...more
The Department of Health and Human Services, Office of Inspector General (OIG) recently issued an Advisory Opinion analyzing an arrangement where a drug manufacturer (the “Requestor”) provides financial assistance to cover...more